The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-02 and is reviewed periodically as new material appears.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
=== Major versus minor === Major cross-match: Here the Recipient serum is tested against donor packed cells to determine if the recipient has preformed antibodies against any antigens on the donor's cells. This is the required cross-match prior to release of a unit of packed cell from blood bank. Minor cross-match: Here the Recipient red cells are tested against donor serum to detect donor antibodies directed against a patient's antigens. This is no longer required. It is assumed that the small amount of donor serum and antibodies left in a unit of packed cells will be diluted in a recipient.
Collision induced unfolding (CIU) is a technique in which an ion's internal energy is increased through collisions with a buffer gas prior to IM-MS analysis. Unfolding of the ion is observed through larger CCSs, and the energy at which unfolding occurs corresponds partially to noncovalent interactions within the ion. This technique has been used to differentiate polyubiquitin linkages and intact antibodies.
This consists of a refrigeration cycle, where heat is removed from a low-temperature space or source and rejected to a high-temperature sink with the help of external work, inverse of the thermodynamic power cycle. In the power cycle, heat is supplied from a high-temperature source to the engine, part of the heat being used to produce work and the rest being rejected to a low-temperature sink. This satisfies the second law of thermodynamics. A refrigeration cycle describes the changes that take place in the refrigerant as it alternately absorbs and rejects heat as it circulates through a refrigerator. It is also applied to heating, ventilation, and air conditioning HVACR work, when describing the "process" of refrigerant flow through an HVACR unit, whether it is a packaged or split system. Heat naturally flows from hot to cold. Work is applied to cool a living space or storage volume by pumping heat from a lower temperature heat source into a higher temperature heat sink. Insulation is used to reduce the work and energy needed to achieve and maintain a lower temperature in the cooled space. The operating principle of the refrigeration cycle was described mathematically by Sadi Carnot in 1824 as a heat engine. The most common types of refrigeration systems use the reverse-Rankine vapor-compression refrigeration cycle, although absorption heat pumps are used in a minority of applications. Cyclic refrigeration can be classified as:
== Interactions == Monoamine oxidase inhibitors (MAOIs) taken with amphetamine may result in a hypertensive crisis if taken within two weeks after last use of an MAOI type drug. Inhibitors of enzymes that directly metabolize amphetamine (particularly CYP2D6 and FMO3) will prolong the elimination of amphetamine and increase drug effects. Serotonergic drugs (such as most antidepressants) co-administered with amphetamine increases the risk of serotonin syndrome. Stimulants and antidepressants (sedatives and depressants) may increase (decrease) the drug effects of amphetamine, and vice versa. Gastrointestinal and urinary pH affect the absorption and elimination of amphetamine, respectively. Gastrointestinal alkalinizing agents increase the absorption of amphetamine. Urinary alkalinizing agents increase the concentration of non-ionized species, decreasing urinary excretion. Proton-pump inhibitors (PPIs) modify the absorption of Adderall XR and Mydayis. Zinc supplementation may reduce the minimum effective dose of amphetamine when it is used for the treatment of ADHD. Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have been found to reduce the stimulant, euphoriant, and sympathomimetic effects of dextroamphetamine in humans.
Sources: en.wikipedia.org
== Applications == Bayesian Inference has extensively been used by molecular phylogeneticists for a wide number of applications. Some of these include: Inference of phylogenies. Inference and evaluation of uncertainty of phylogenies. Inference of ancestral character state evolution. Inference of ancestral areas. Molecular dating analysis. Model dynamics of species diversification and extinction Elucidate patterns in pathogens dispersal. Inference of phenotypic trait evolution.
Followers of Jainism practice a strict lacto-vegetarian diet deeply rooted in the fundamental ethical principle of nonviolence (ahimsa). Unlike many other dietary frameworks, Jain vegetarianism operates on a rigorous biological taxonomy that categorizes lifeforms by their number of sense organs, ranging from one-sensed organisms (ekendriya jiva, such as plants and water) to five-sensed beings (panchendriya jiva, such as mammals and humans). The overarching dietary goal is to completely eliminate violence against higher-sensed beings (meat, fish, and eggs) while strictly minimizing harm to single-sensed organisms and microscopic life. To achieve this, the diet extends significantly beyond standard vegetarianism. Jains strictly avoid root and underground vegetables—such as potatoes, onions, and garlic—because harvesting them requires uprooting and killing the entire plant, and disrupts massive clusters of microscopic lifeforms (nigoda) that thrive in the soil and root systems. The consumption of honey is absolutely forbidden due to the violent disruption of the hive during extraction and because its viscous nature makes it a breeding ground for microorganisms. Similarly, fungi (mushrooms) and multi-seeded vegetables (like eggplant) are avoided to prevent the ingestion of mobile insects (trasa jiva) and microscopic life. Furthermore, Jain dietary law prohibits the consumption of products derived from already-dead animals.
== Further reading == Gherasim C, Lofgren M, Banerjee R (May 2013). "Navigating the B(12) road: assimilation, delivery, and disorders of cobalamin". J. Biol. Chem. 288 (19): 13186–13193. doi:10.1074/jbc.R113.458810. PMC 3650358. PMID 23539619.
=== Laboratory tests === Serum creatine kinase (CK) is the most commonly used biomarker of muscle injury, and is often supplemented by aldolase, lactate dehydrogenase and the aminotransferases. However, elevated CK is not specific to myopathy, and isolated raised CK ("hyperCKemia") has a poor diagnostic yield on its own. Where an idiopathic inflammatory myopathy is suspected, testing for myositis-specific autoantibodies (MSAs) is recommended, ideally before starting immunosuppression, as these antibodies define distinct clinical subtypes and patterns of organ involvement.
=== Dicamba lawsuit === On 27 January 2020, the first-ever lawsuit concerning Dicamba-related products began in Cape Girardeau, Missouri. The lawsuit involved a peach farmer who alleged that Dicamba-based herbicides caused significant damage to his crops and trees. It had also been filed in November 2016, when Dicamba was still owned by Monsanto. On 14 February 2020, the jury involved in the lawsuit ruled against BASF and its co-defendant Bayer, which had acquired Monsanto and its products, and found in favor of the peach grower, Bader Farms owner Bill Bader. BASF and Bayer were also ordered to pay Bader $15 million in damages. On 15 February 2020, Monsanto and BASF were ordered to pay an additional $250 million in punitive damages.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.